Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
Atara Biotherapeutics (Nasdaq: ATRA), a pioneer in T-cell immunotherapy focusing on EBV T-cell platform for cancer and autoimmune disease treatments, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. Cokey Nguyen, Ph.D., President and CEO, will engage in a fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. EST. The presentation will be accessible via live webcast in the Investors and Media section of atarabio.com, with a replay available for 30 days afterward.
Atara Biotherapeutics (Nasdaq: ATRA), un pioniere nella immunoterapia con cellule T focalizzata sulla piattaforma EBV T-cell per il trattamento di tumori e malattie autoimmuni, ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore ISI HealthCONx. Cokey Nguyen, Ph.D., Presidente e CEO, parteciperà a una conversazione informale martedì 3 dicembre 2024, alle 15:50 EST. La presentazione sarà disponibile tramite webcast in diretta nella sezione Investitori e Media di atarabio.com, con una registrazione accessibile per 30 giorni dopo.
Atara Biotherapeutics (Nasdaq: ATRA), un pionero en la inmunoterapia con células T enfocado en la plataforma EBV T-cell para tratamientos de cáncer y enfermedades autoinmunes, ha anunciado su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. Cokey Nguyen, Ph.D., Presidente y CEO, participará en un chat informal el martes 3 de diciembre de 2024, a las 3:50 p.m. EST. La presentación será accesible a través de una transmisión web en vivo en la sección de Inversores y Medios de atarabio.com, con una repetición disponible durante 30 días después.
Atara Biotherapeutics (Nasdaq: ATRA)는 암 및 자가 면역 질환 치료를 위한 EBV T-cell 플랫폼에 중점을 둔 T세포 면역 요법의 선두주자로서 제7회 Evercore ISI HealthCONx 콘퍼런스에 참여한다고 발표했습니다. Cokey Nguyen, Ph.D., 사장 겸 CEO는 2024년 12월 3일 화요일 오후 3시 50분 EST에 대화에 참여할 예정입니다. 발표는 atarabio.com의 투자자 및 미디어 섹션에서 실시간 웹캐스트를 통해 시청할 수 있으며, 이후 30일 동안 재생이 가능합니다.
Atara Biotherapeutics (Nasdaq: ATRA), un pionnier dans l'immunothérapie par cellules T axée sur la plateforme de cellules T EBV pour les traitements du cancer et des maladies auto-immunes, a annoncé sa participation à la 7e Conférence Annuelle Evercore ISI HealthCONx. Cokey Nguyen, Ph.D., Président et CEO, participera à une discussion informelle le mardi 3 décembre 2024, à 15h50 EST. La présentation sera accessible via un webcast en direct dans la section Investisseurs et Médias de atarabio.com, avec une rediffusion disponible pendant 30 jours par la suite.
Atara Biotherapeutics (Nasdaq: ATRA), ein Pionier in der T-Zell-Immuntherapie, die sich auf die EBV T-cell Plattform für die Behandlung von Krebs und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an der 7. Jahrestagung der Evercore ISI HealthCONx angekündigt. Cokey Nguyen, Ph.D., Präsident und CEO, wird am Dienstag, den 3. Dezember 2024, um 15:50 Uhr EST in einem Fireside-Chat teilnehmen. Die Präsentation wird über einen Live-Webcast im Bereich Investoren und Medien auf atarabio.com zugänglich sein, mit einer Wiederholung, die 30 Tage lang verfügbar ist.
- None.
- None.
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241127591668/en/
Investor and Media Relations:
Jason Awe, Ph.D.
Head of Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
When is Atara Biotherapeutics (ATRA) presenting at the Evercore ISI HealthCONx Conference 2024?
How can investors watch Atara Biotherapeutics' (ATRA) presentation at the HealthCONx Conference?
What type of therapies is Atara Biotherapeutics (ATRA) developing?
